Outline
- Clinically relevant specifications: when is this important?
- The role of biopharmaceutics risk assessment
- How do we build clinical relevance into RTRT dissolution
models?- Conventional approaches
- The relevance of mechanistic modeling and simulation
(e.g., physiologically based biopharmaceutics modeling [PBBM])
- Take home message
By Sandra Suarez-Sharp
Presented at IFPAC 2022 North Bethesda, Maryland June 15, 2022